The biopharmaceutical sector is transitioning from reactive off-line quality control to a proactive quality by design (QbD) framework. Process analytical technology (PAT) enables this shift through ...
Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") reported fourth quarter 2025 revenue of ...
A machine learning model incorporating functional assessments predicts one-year mortality in older patients with HF and improves risk stratification beyond established scores. Functional status at ...
Upregulated expression of transcription factors promoting cone identity in late-stage retinal progenitors drives development ...
The FDA announced it planned to restrict use of GLP-1 active pharmaceutical ingredients in non-FDA-approved drugs, including those from Hims & Hers and other compounding pharmacies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results